NCT06122493View on ClinicalTrials.gov

Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

November 1, 2026

Study Completion Date

November 1, 2026

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Tirelizumab

immunotherapy, 200 mg on day 1 per 3 weeks

DRUG

Nab paclitaxel

chemotherapy, 175 mg/m² on day 1 per 3 weeks

DRUG

Carboplatin

chemotherapy, AUC=5 on day 1 per 3 weeks

RADIATION

Radiotherapy

Patients without disease progression after four cycles of chemoimmunotherapy receive radiotherapy targeting esophageal lesions and positive lymph nodes, with a total dose of 50.4 Gy delivered over 28 fractions.

Trial Locations (1)

200025

RECRUITING

Ruijin hospital, Shanghai jiaotong university school of medicine, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER